In a child with SVT who deteriorates during treatment and has a rapid, weak femoral pulse, which action is indicated?

In a child with SVT who deteriorates during treatment and has a rapid, weak femoral pulse, which action is indicated?

• A. Immediate synchronized cardioversion
• B. Administer adenosine intravenously
• C. Start manual external pacing
• D. Observe and monitor

Answer: (A)

In a child with SVT who is deteriorating and has signs of poor perfusion (rapid, weak femoral pulse), the priority is to rapidly restore a stable heart rhythm with synchronized cardioversion. The presence of a pulse but ongoing instability means you should not delay for drugs; synchronized cardioversion delivers a timed shock that can quickly terminate the tachycardia and improve perfusion. Adenosine is useful for stable, narrow-complex SVT to transiently block AV nodal conduction and potentially terminate the arrhythmia. However, in a patient who is deteriorating with poor perfusion, using a drug to try to terminate the rhythm may delay definitive treatment and can cause transient hypotension or other adverse effects without providing the rapid hemodynamic improvement that cardioversion offers. Manual external pacing targets bradycardia, not SVT, and observing without intervention won’t reverse the instability. With synchronized cardioversion, deliver a shock in rhythm with the QRS complex to avoid inducing ventricular fibrillation, and start at the recommended pediatric energy dose (typically 0.5–1 J/kg, increasing to 2 J/kg if needed), repeating as necessary until perfusion improves and a stable rhythm is achieved.

In a child with SVT who is deteriorating and has signs of poor perfusion (rapid, weak femoral pulse), the priority is to rapidly restore a stable heart rhythm with synchronized cardioversion. The presence of a pulse but ongoing instability means you should not delay for drugs; synchronized cardioversion delivers a timed shock that can quickly terminate the tachycardia and improve perfusion.

Adenosine is useful for stable, narrow-complex SVT to transiently block AV nodal conduction and potentially terminate the arrhythmia. However, in a patient who is deteriorating with poor perfusion, using a drug to try to terminate the rhythm may delay definitive treatment and can cause transient hypotension or other adverse effects without providing the rapid hemodynamic improvement that cardioversion offers. Manual external pacing targets bradycardia, not SVT, and observing without intervention won’t reverse the instability.

With synchronized cardioversion, deliver a shock in rhythm with the QRS complex to avoid inducing ventricular fibrillation, and start at the recommended pediatric energy dose (typically 0.5–1 J/kg, increasing to 2 J/kg if needed), repeating as necessary until perfusion improves and a stable rhythm is achieved.